Depemokimab for allergic bronchopulmonary aspergillosis with severe asthma
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study looks at how well a new injectable medicine called depemokimab works for people who have both allergic bronchopulmonary aspergillosis (ABPA) and severe eosinophilic asthma. It aims to see if this medication helps control symptoms and reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus.
- You must have severe asthma that is treated with high-dose inhaled steroids plus another controller medication, or you need daily or every-other-day steroid pills to keep your asthma under control.
- You cannot be allergic to the study drug, depemokimab, or its components.
- You cannot be pregnant or breastfeeding.
- You cannot be enrolled in another interventional study at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether tezepelumab, a biologic medication, can help people with allergic bronchopulmonary aspergillosis (ABPA) and severe asthma. It aims to reduce asthma attacks and improve breathing.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This trial compares three treatments for ABPA: a steroid (prednisolone), an antifungal (itraconazole), or both together. It aims to find which works best for controlling symptoms and preventing flare-ups.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
Hear when a new Allergic Bronchopulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.